Upcoming Site Maintenance on Tuesday, May 28, 2024: Please note that some site functionality such as new user registrations, updates to user accounts, and article purchases will be unavailable during maintenance on this date.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyAdult Urology1 Dec 2013

Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population

    View All Author Information


    Patients with locally advanced prostate cancer after radical prostatectomy are candidates for secondary therapy. However, this higher risk population is heterogeneous. Many cases do not metastasize even when conservatively managed. Given the limited specificity of pathological features to predict metastasis, newer risk prediction models are needed. We report a validation study of a genomic classifier that predicts metastasis after radical prostatectomy in a high risk population.

    Materials and Methods:

    A case-cohort design was used to sample 1,010 patients after radical prostatectomy at high risk for recurrence who were treated from 2000 to 2006. Patients had preoperative prostate specific antigen greater than 20 ng/ml, Gleason 8 or greater, pT3b or a Mayo Clinic nomogram score of 10 or greater. Patients with metastasis at diagnosis or any prior treatment for prostate cancer were excluded from analysis. A 20% random sampling created a subcohort that included all patients with metastasis. We generated 22-marker genomic classifier scores for 219 patients with available genomic data. ROC and decision curves, competing risk and weighted regression models were used to assess genomic classifier performance.


    The genomic classifier AUC was 0.79 for predicting 5-year metastasis after radical prostatectomy. Decision curves showed that the genomic classifier net benefit exceeded that of clinical only models. The genomic classifier was the predominant predictor of metastasis on multivariable analysis. The cumulative incidence of metastasis 5 years after radical prostatectomy was 2.4%, 6.0% and 22.5% in patients with low (60%), intermediate (21%) and high (19%) genomic classifier scores, respectively (p <0.001).


    Results indicate that genomic information from the primary tumor can identify patients with adverse pathological features who are most at risk for metastasis and potentially lethal prostate cancer.


    • 1 : International variation in prostate cancer incidence and mortality rates. Eur Urol2012; 61: 1079. Google Scholar
    • 2 : Prostate cancer epidemiology in the United States. World J Urol2012; 30: 195. Google Scholar
    • 3 : Cancer statistics, 2012. CA Cancer J Clin2012; 62: 10. Google Scholar
    • 4 : Prognostic factors for failure after prostatectomy. J Cancer2011; 2: 1. Google Scholar
    • 5 : Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med2010; 170: 1390. Google Scholar
    • 6 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Crossref, MedlineGoogle Scholar
    • 7 : High-risk prostate cancer: from definition to contemporary management. Eur Urol2012; 61: 1096. Google Scholar
    • 8 : Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol2009; 181: 956. LinkGoogle Scholar
    • 9 : Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet2012; 380: 2018. Google Scholar
    • 10 : Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol2009; 27: 2924. Google Scholar
    • 11 : The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol2012; 2012: 612707. Google Scholar
    • 12 : Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol2004; 172: 910. LinkGoogle Scholar
    • 13 : Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol2011; 59: 893. Google Scholar
    • 14 : Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol2011; 185: 116. LinkGoogle Scholar
    • 15 : Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence. J Urol2013; 189: e918. AbstractGoogle Scholar
    • 16 : Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One2013; 8: e66855. Google Scholar
    • 17 : Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?. J Urol2007; 178: 459. LinkGoogle Scholar
    • 18 : Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol2005; 23: 7005. Google Scholar
    • 19 : Cox regression with incomplete covariate measurements. J Am Stat Ass1993; 88: 1341. Google Scholar
    • 20 : A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc1999; 94: 496. Google Scholar
    • 21 : The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer2011; 117: 5039. Google Scholar
    • 22 : Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget2013; 4: 600. Google Scholar
    • 23 : Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol2009; 27: 4300. Google Scholar
    • 24 : Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn2010; 10: 49. Google Scholar
    • 25 : Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol2011; 12: 245. Google Scholar
    • 26 : Genomic “dark matter” in prostate cancer: exploring the clinical utility of ncRNA as biomarkers. Front Genet2012; 3: 23. Google Scholar
    • 27 : Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol2011; 29: 742. Google Scholar
    • 28 : Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer2011; 117: 4855. Google Scholar
    • 29 : Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2012; 157: 120. Google Scholar
    • 30 : Initial Report of RTOG 9601: A phase III trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels. Int J Radiat Oncol Biol Physics2010; 78: S27. Google Scholar